Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The cost of improving outcomes in COPD

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    The cost of improving outcomes in COPD. Pharmacoecon. Outcomes News 464, 3–4 (2004). https://doi.org/10.2165/00151234-200404640-00005

    Download citation

    Keywords

    • Chronic Obstructive Pulmonary Disease
    • Chronic Obstructive Pulmonary Disease Patient
    • Fluticasone
    • Fluticasone Propionate
    • Salmeterol